Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Expression of the SART-1 antigens in uterine cancers.

Literature DB >> 10081490

Expression of the SART-1 antigens in uterine cancers.

H Matsumoto¹, S Shichijo, K Kawano, T Nishida, M Sakamoto, K Itoh.

Abstract

We recently reported that the SART-1 gene, encoding the SART-1(259) tumor antigen which is recognized by HLA-A26-restricted cytotoxic T lymphocytes (CTLs), is expressed in the cytosol of squamous cell carcinomas and adenocarcinomas. The present study deals with the expression of SART-1(259) and SART-1(800) antigens in uterine cancers. The SART-1(259) antigen was detected in the cytosol fraction of 4 of 8 uterine cancer cell lines, 24 of 74 (32%) uterine cancer tissues, 0 of 7 uterine myomas, and 0 of 5 non-tumorous uterine tissues. The SART-1(800) antigen was expressed in the nuclear fraction of all the uterine cancer cell lines, 41 of 74 (55%) uterine cancer tissues, 0 of 7 myomas, and 3 of 5 non-tumorous uterine tissues. The SART-1(259)+ uterine cancer cells were recognized by HLA-A24 restricted and SART-1 specific CTLs. Therefore, SART-1(259) antigen could be an appropriate vaccine candidate for a relatively large number of uterine cancer patients.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1998 PMID： 10081490 PMCID： PMC5921731 DOI： 10.1111/j.1349-7006.1998.tb00526.x

Source DB: PubMed Journal: Jpn J Cancer Res ISSN： 0910-5050

9 in total

1. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3.

Authors: M Marchand; P Weynants; E Rankin; F Arienti; F Belli; G Parmiani; N Cascinelli; A Bourlond; R Vanwijck; Y Humblet
Journal: Int J Cancer Date: 1995-12-11 Impact factor: 7.396

2. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors: S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal: Nat Med Date: 1998-03 Impact factor: 53.440

3. CD8+ T lymphocytes are recruited to neoplastic cervix.

Authors: M C Bell; R P Edwards; E E Partridge; K Kuykendall; W Conner; H Gore; E Turbat-Herrara; P A Crowley-Nowick
Journal: J Clin Immunol Date: 1995-05 Impact factor: 8.317

4. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

Authors: F O Nestle; S Alijagic; M Gilliet; Y Sun; S Grabbe; R Dummer; G Burg; D Schadendorf
Journal: Nat Med Date: 1998-03 Impact factor: 53.440

5. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors: P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal: Science Date: 1991-12-13 Impact factor: 47.728

6. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Authors: Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; L Rivoltini; S L Topalian; T Miki; S A Rosenberg
Journal: Proc Natl Acad Sci U S A Date: 1994-04-26 Impact factor: 11.205

1 in total

1. Expression of tumor-rejection antigens in gynecologic cancers.

Authors: S Tanaka; N Tsuda; K Kawano; M Sakamoto; T Nishida; T Hashimoto; S Shichijo; T Kamura; K Itoh
Journal: Jpn J Cancer Res Date: 2000-11